ACADIA to Host Conference Call and Webcast on Thursday, February 27,2014, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Feb. 20, 2014—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in neurological and related centralnervous system disorders, today announced that it will report itsfinancial results for the fourth quarter and year ended December 31,2013 on Thursday, February 27, 2014, after the U.S. financial marketsclose. ACADIA's management will host a conference call and webcast onThursday, February 27, 2014, at 5:00 p.m. Eastern Time to discussACADIA’s financial results and development programs.
The conference call may be accessed by dialing 800-706-7741 forparticipants in the U.S. or Canada and 617-614-3471 for internationalcallers (reference passcode 12002019). A telephone replay of theconference call may be accessed through March 13, 2014 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 39435923). The conference callalso will be webcast live on ACADIA’s website, www.acadia-pharm.com,under the investors section and will be archived there until March 13,2014.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines that address unmet medicalneeds in neurological and related central nervous system disorders.ACADIA has a pipeline of product candidates led by pimavanserin, whichis in Phase III development as a potential first-in-class treatment forParkinson’s disease psychosis. Pimavanserin is also in Phase IIdevelopment for Alzheimer’s disease psychosis and has successfullycompleted a Phase II trial as a co-therapy for schizophrenia. ACADIAalso has clinical-stage programs for chronic pain and glaucoma incollaboration with Allergan, Inc. and two advanced preclinical programsdirected at Parkinson’s disease and other neurological disorders. Allproduct candidates are small molecules that emanate from internaldiscoveries. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, either alone or with a partner,including clinical trials, and the benefits to be derived from ACADIA’sproduct candidates, in each case including pimavanserin. Thesestatements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks anduncertainties inherent in drug discovery, development andcommercialization, and collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA’s annual report on Form 10-K for the year ended December 31, 2012as well as ACADIA’s subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, ExecutiveVice President,
Chief Financial Officer and Chief BusinessOfficer
Lisa Barthelemy, Director of Investor Relations
858-558-2871